EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort

Simone Negrini iD, Stefania Nicola, Francesco Sardanapoli, Rocco Francesco Rinaldo iD, Marco Russo, Iuliana Badiu, Anna Quinternetto, Luca Lo Sardo iD, Francesco Blasi iD, Pierluigi Paggiaro, Enrico Heffler iD, Giovanni Rolla iD und 5 weitere

Medical Sciences · 2026

DOI: 10.3390/medsci14050523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, 2026. Verfasst von Simone Negrini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Allergy Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, 10128 Turin, Italy. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical remission is an emerging therapeutic goal in severe asthma treated with biologics. However, remission may evolve beyond the conventional 12-month assessment, and limited real-world data are available on patients who continue the same biologic after incomplete remission at 12 months. We evaluated longitudinal remission trajectories in patients with severe T2-high asthma continuing the same biologic therapy.

Methods

This retrospective real-world single-center SANI cohort included adults with severe asthma treated with one biologic agent and followed for at least 18 months. Clinical outcomes and remission status were assessed at 12 and 18 months according to the SANI definition, distinguishing complete remission, partial remission, and no remission.

Results

The cohort included 146 patients; 64.4% were female, median age was 61 years, and all had a T2-high phenotype. Maintenance oral corticosteroid use decreased from 83.6% at baseline to 6.8% at 18 months, while symptomatic patients decreased from 100.0% to 11.0%. Median ACT improved from 12.0 to 22.0, and patients with ≥1 exacerbation decreased to 4.1% at 18 months. Complete remission increased from 36.3% at 12 months to 67.1% at 18 months, while no remission decreased from 54.1% to 16.4%. Among patients not in remission at 12 months, 43.0% achieved complete remission and 26.6% achieved partial remission at 18 months. Baseline oral corticosteroid use was associated with lower remission likelihood, whereas preserved baseline FEV1 favored remission at 18 months.

Conclusions

Among patients with severe T2-high asthma selected for continuing an unchanged biologic for at least 18 months, remission status was more favorable at 18 months than at 12 months. This observation describes the trajectory of biologic continuers and should not be generalized to all patients who remain outside remission at 12 months. Because patients who discontinued or switched biologics were excluded, these data do not establish that continuation is preferable to switching after an incomplete 12-month response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsAnti-Asthmatic AgentsHumansFemaleMiddle AgedRemission InductionMaleRetrospective StudiesAgedTreatment OutcomeAdultSeverity of Illness IndexAdrenal Cortex Hormones

Stichwörter der Autor:innen

biologic therapyclinical remissionoral corticosteroidsreal-world evidencesevere asthmatype 2 inflammation

Substanzen

Biological ProductsAnti-Asthmatic AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Immunology and Allergy Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, 10128 Turin, Italy.
  • Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Pneumology Unit, City of Health and Science, Molinette Hospital, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20100 Milan, Italy.
  • Respiratory and Cystic Fibrosis Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, 20100 Milan, Italy.
  • Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, 56100 Pisa, Italy.

ORCID-Profile: Simone Negrini, Rocco Francesco Rinaldo, Luca Lo Sardo, Francesco Blasi, Enrico Heffler, Giovanni Rolla, Caterina Bucca, Giorgio Walter Canonica, Paolo Solidoro, Luisa Brussino

Zitieren

APA

Negrini, S., Nicola, S., Sardanapoli, F., Rinaldo, R. F., Russo, M., Badiu, I., Quinternetto, A., Lo Sardo, L., Blasi, F., Paggiaro, P., Heffler, E., Rolla, G., Bucca, C., Canonica, G. W., Ribolla, F., Solidoro, P., & Brussino, L. (2026). Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort. Medical Sciences. https://doi.org/10.3390/medsci14050523

Vancouver

Negrini S, Nicola S, Sardanapoli F, Rinaldo RF, Russo M, Badiu I, et al. Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort. Medical Sciences. 2026. doi:10.3390/medsci14050523

BibTeX
@article{Negrini2026,
  author = {Negrini, Simone and Nicola, Stefania and Sardanapoli, Francesco and Rinaldo, Rocco Francesco and Russo, Marco and Badiu, Iuliana and Quinternetto, Anna and Lo Sardo, Luca and Blasi, Francesco and Paggiaro, Pierluigi and Heffler, Enrico and Rolla, Giovanni and Bucca, Caterina and Canonica, Giorgio Walter and Ribolla, Fulvia and Solidoro, Paolo and Brussino, Luisa},
  title = {Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14050523}
}
Kostenlos starten →